Literature DB >> 20529135

Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.

A Wagg1, C Verdejo, U Molander.   

Abstract

Overactive bladder (OAB) will become an increasingly prevalent problem as the proportion of older people in the population increases over the next 20 years. In addition to the urological symptoms (urinary urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia), OAB is associated with other problems in older patients, especially an increased risk of falls and fractures. The bother caused by OAB needs not be an inevitable consequence of ageing, because the symptoms can usually be alleviated, even in frail older people. Pharmacological treatment for OAB involves the use of antimuscarinic agents, whose efficacy and safety profiles depend on their interactions with muscarinic receptors that are widely distributed throughout the body. Interactions between antimuscarinics and M(1) receptors in the central nervous system may have the potential to cause cognitive impairment in older people, depending on muscarinic receptor binding profiles, lipophilicity and the ability to cross the blood brain barrier. Concerns over the possibility of cognitive impairment have contributed to an under-utilisation of antimuscarinics in the geriatric population, despite the high prevalence and severity of OAB in older subjects. Antimuscarinic agents should be actively considered for elderly patients with OAB, but it is desirable to establish the cognitive risk for every type of antimuscarinic, using robust cognition assessment methods.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20529135     DOI: 10.1111/j.1742-1241.2010.02449.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  23 in total

Review 1.  Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.

Authors:  Scott Martin Vouri; Clark D Kebodeaux; Paul M Stranges; Besu F Teshome
Journal:  Arch Gerontol Geriatr       Date:  2016-11-14       Impact factor: 3.250

Review 2.  Neurogenic lower urinary tract dysfunction: evaluation and management.

Authors:  Katarina Ivana Tudor; Ryuji Sakakibara; Jalesh N Panicker
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

3.  Treating overactive bladder in the elderly.

Authors:  Adrian Wagg
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

4.  Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.

Authors:  Scott Martin Vouri; Mario Schootman; Seth A Strope; Stanley J Birge; Margaret A Olsen
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

Review 5.  Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.

Authors:  Dustin Pagoria; R Corey O'Connor; Michael L Guralnick
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 6.  Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.

Authors:  Adrian Wagg; Matthias Oelke; Javier C Angulo; David Scholfield; Daniel Arumi
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

7.  Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Authors:  Sender Herschorn; Jameel Nazir; Barbara Ramos; Zalmai Hakimi
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

8.  Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.

Authors:  Nandita Kachru; Sneha Sura; Satabdi Chatterjee; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

Review 9.  OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.

Authors:  Hann-Chorng Kuo
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

10.  Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.

Authors:  Thomas O Schrader; Yifeng Xiong; Ariana O Lorenzana; Alexander Broadhead; Karin J Stebbins; Michael M Poon; Christopher Baccei; Daniel S Lorrain
Journal:  ACS Med Chem Lett       Date:  2020-12-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.